New RNA drug takes aim at tough bladder cancer

NCT ID NCT06351904

Recruiting now Disease control Sponsor: Ractigen Therapeutics. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing a new drug called RAG-01 in 72 people with a type of bladder cancer that has not responded to standard therapy. The drug uses a small RNA molecule to try to control the cancer. The main goals are to check safety and find the right dose, while also looking for early signs that it might work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RAG-01 (a small activating RNA drug)
What this could lead to: If it works, this could point toward a new treatment option for bladder cancer patients who have not responded to standard therapy.
What could go wrong: This is an early Phase 1 trial with only 72 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

Contacts and locations

Locations

GenesisCare North Shore
RECRUITING

St Leonards, New South Wales, 2065, Australia
Peninsula & South Eastern Haematology and Oncology Group
RECRUITING

Melbourne, Victoria, 3199, Australia
The Royal Melbourne Hospital
RECRUITING

Melbourne, Victoria, 3050, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.